{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:27:04Z","timestamp":1786976824399,"version":"build-2736575974"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp; Dementia"],"published-print":{"date-parts":[[2021,6]]},"abstract":"Abstract<\/jats:title>\n \n Numerous clinical trials of anti\u2010amyloid beta (A\u03b2) immunotherapy in Alzheimer's disease have been performed. None of these have provided convincing evidence for beneficial effects. Using traditional frequentist meta\u2010analysis, the conclusion is that there is\n absence of evidence<\/jats:italic>\n for a therapeutic effect, with a point estimate effect size of 0.05 (95% confidence interval \u22120.00 to 0.10,\n P<\/jats:italic>\n \u00a0=\u00a0.055). In addition, this non\u2010significant effect equates to 0.4 points per year on the cognitive subscale of the Alzheimer's Disease Assessment Scale. This is well below the minimally clinically important difference. Bayesian meta\u2010analysis of these trial data provides strong\n evidence of absence<\/jats:italic>\n of a therapeutic effect, with a Bayes factor of 11.27 in favor of the null hypothesis, opposed to a Bayes factor of 0.09 in favor of a treatment effect. Bayesian analysis is particularly valuable in this context of repeatedly reported small, non\u2010significant effect sizes in individual trials. Mechanisms other than removal of A\u03b2 from the brain may be probed to slow progression of Alzheimer's disease.\n <\/jats:p>","DOI":"10.1002\/alz.12379","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T05:54:21Z","timestamp":1622440461000},"page":"1051-1055","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Bayes analysis supports null hypothesis of anti\u2010amyloid beta therapy in Alzheimer's disease"],"prefix":"10.1002","volume":"17","author":[{"given":"Edo","family":"Richard","sequence":"first","affiliation":[{"name":"Department of Neurology, Radboud University Medical Center Donders Institute for Brain, Cognition, and Behaviour Nijmegen the Netherlands"},{"name":"Department of Public and Occupational Health Amsterdam University Medical Centre AMC University of Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina G.H.E.","family":"den Brok","sequence":"additional","affiliation":[{"name":"Department of Neurology, Radboud University Medical Center Donders Institute for Brain, Cognition, and Behaviour Nijmegen the Netherlands"},{"name":"Department of Neurology Amsterdam University Medical Centre AMC University of Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A.","family":"van Gool","sequence":"additional","affiliation":[{"name":"Department of Public and Occupational Health Amsterdam University Medical Centre AMC University of Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593\u2010020\u20100660\u20104"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2019.1665738"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010017\u20100318\u2010y"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz142"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150070147"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa325"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"}],"container-title":["Alzheimer's & Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.12379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:36:05Z","timestamp":1759865765000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.12379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/alz.12379"],"URL":"https:\/\/doi.org\/10.1002\/alz.12379","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"2021-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}